vs
Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
BridgeBio Pharma, Inc. is the larger business by last-quarter revenue ($154.2M vs $151.1M, roughly 1.0× STURM RUGER & CO INC). On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs 3.6%). STURM RUGER & CO INC produced more free cash flow last quarter ($12.3M vs $-56.5M).
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
BBIO vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $151.1M |
| Net Profit | $-194.6M | — |
| Gross Margin | 94.7% | 17.8% |
| Operating Margin | -90.5% | 2.3% |
| Net Margin | -126.2% | — |
| Revenue YoY | 2521.2% | 3.6% |
| Net Profit YoY | 27.2% | — |
| EPS (diluted) | $-1.00 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.2M | $151.1M | ||
| Q3 25 | $120.7M | $126.8M | ||
| Q2 25 | $110.6M | $132.5M | ||
| Q1 25 | $116.6M | $135.7M | ||
| Q4 24 | — | $145.8M | ||
| Q3 24 | — | $122.3M | ||
| Q2 24 | — | $130.8M | ||
| Q1 24 | $211.1M | $136.8M |
| Q4 25 | $-194.6M | — | ||
| Q3 25 | $-184.9M | $1.6M | ||
| Q2 25 | $-183.8M | $-17.2M | ||
| Q1 25 | $-169.6M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | $-36.2M | $7.1M |
| Q4 25 | 94.7% | 17.8% | ||
| Q3 25 | 94.6% | 15.1% | ||
| Q2 25 | 96.7% | 3.9% | ||
| Q1 25 | 97.7% | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | 99.7% | 21.5% |
| Q4 25 | -90.5% | 2.3% | ||
| Q3 25 | -120.3% | -2.7% | ||
| Q2 25 | -121.4% | -15.6% | ||
| Q1 25 | -89.5% | 6.2% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | 0.2% | 5.5% |
| Q4 25 | -126.2% | — | ||
| Q3 25 | -153.2% | 1.2% | ||
| Q2 25 | -166.2% | -13.0% | ||
| Q1 25 | -145.4% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | -17.1% | 5.2% |
| Q4 25 | $-1.00 | $0.22 | ||
| Q3 25 | $-0.95 | $0.10 | ||
| Q2 25 | $-0.95 | $-1.05 | ||
| Q1 25 | $-0.88 | $0.46 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | — | $0.47 | ||
| Q1 24 | $-0.20 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $570.1M | $92.5M |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $-2.1B | $283.8M |
| Total Assets | $936.0M | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $570.1M | $92.5M | ||
| Q3 25 | $643.0M | $80.8M | ||
| Q2 25 | $756.9M | $101.4M | ||
| Q1 25 | $540.6M | $108.3M | ||
| Q4 24 | — | $105.5M | ||
| Q3 24 | — | $96.0M | ||
| Q2 24 | — | $105.6M | ||
| Q1 24 | $519.7M | $115.3M |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-2.1B | $283.8M | ||
| Q3 25 | $-1.9B | $279.6M | ||
| Q2 25 | $-1.8B | $289.3M | ||
| Q1 25 | $-1.6B | $321.5M | ||
| Q4 24 | — | $319.6M | ||
| Q3 24 | — | $314.9M | ||
| Q2 24 | — | $321.5M | ||
| Q1 24 | $-1.0B | $332.0M |
| Q4 25 | $936.0M | $342.0M | ||
| Q3 25 | $998.3M | $342.3M | ||
| Q2 25 | $1.1B | $349.5M | ||
| Q1 25 | $881.6M | $379.0M | ||
| Q4 24 | — | $384.0M | ||
| Q3 24 | — | $373.5M | ||
| Q2 24 | — | $376.7M | ||
| Q1 24 | $849.3M | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-56.4M | $15.5M |
| Free Cash FlowOCF − Capex | $-56.5M | $12.3M |
| FCF MarginFCF / Revenue | -36.6% | 8.2% |
| Capex IntensityCapex / Revenue | 0.0% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-56.4M | $15.5M | ||
| Q3 25 | $-109.6M | $12.9M | ||
| Q2 25 | $-80.7M | $14.7M | ||
| Q1 25 | $-199.2M | $11.1M | ||
| Q4 24 | — | $20.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | $-219.5M | $7.3M |
| Q4 25 | $-56.5M | $12.3M | ||
| Q3 25 | $-110.0M | $7.0M | ||
| Q2 25 | $-81.3M | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | $-220.2M | $5.6M |
| Q4 25 | -36.6% | 8.2% | ||
| Q3 25 | -91.2% | 5.5% | ||
| Q2 25 | -73.5% | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | -104.3% | 4.1% |
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.4% | 4.6% | ||
| Q2 25 | 0.5% | 4.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | 0.3% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBIO
Segment breakdown not available.
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
